This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Roche to Create Companion Diagnostic Test for Merck's Keytruda
by Zacks Equity Research
Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan
by Zacks Equity Research
JP Morgan downgrades Pfizer (PFE) on assumptions that the market has discounted all growth factors for Pfizer.
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
by Zacks Equity Research
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
Roche's Tecentriq Gets FDA Approval for First-Line NSCLC
by Zacks Equity Research
Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.
Bristol-Myers Squibb (BMY) Stock Moves -0.32%: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $53.08, moving -0.32% from the previous trading session.
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
by Zacks Equity Research
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.
Novartis Presents Additional Data on Breast Cancer Candidate
by Zacks Equity Research
Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.
Roche's Tecentriq Combination Gets Priority Review by FDA
by Zacks Equity Research
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
J&J Strikes Deal with argenx to Co-Develop Cancer Antibody
by Zacks Equity Research
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
The Zacks Analyst Blog Highlights: Shoe Carnival, On Deck, DXP, Arch Coal and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Shoe Carnival, On Deck, DXP, Arch Coal and Bristol-Myers
Shire's Takhzyro Gets European Nod for Hereditary Angioedema
by Zacks Equity Research
Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
5 Best Stocks to Own This December
by Tirthankar Chakraborty
This year's holiday season started on a positive note as consumers have stepped up online purchases, while the United States and China's 90-day trade tariff ceasefire soothed investors.
Novartis' Gilenya Approved in EU for Expanded Population
by Zacks Equity Research
Novartis (NVS) gains the EU approval for MS drug Gilenya for children who are 10-17 years old with relapsing-remitting forms of multiple sclerosis.
Lilly (LLY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bayer (BAYRY) to Restructure Business & Reduce Headcount
by Zacks Equity Research
Bayer (BAYRY) conducts a strategic review of its business model, and plans to exit unprofitable product lines and reduce headcount.
Catalyst's Firdapse Receives FDA Approval for Rare Disease
by Zacks Equity Research
Catalyst's (CPRX) Firdapse gets FDA approval for the treatment of LEMS in adults.
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $52 in the latest trading session, marking a +1.66% move from the prior day.
Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity
by Zacks Equity Research
Pfizer (PFE) receives pediatric exclusivity for its epilepsy drug, Lyrica, extending the exclusivity period to Jun 30, 2019.
Company News For Nov 28, 2018
by Zacks Equity Research
Companies In The News Are: UTX,GM,BMY,SAVE
Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate
by Zacks Equity Research
Alnylam (ALNY) and Vir commence phase I/II study for VIR-2218 for the treatment of chronic HBV infection.
Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial
by Zacks Equity Research
Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with Yervoy fails to meet the goal in a late-stage study for extensive-stage SCLC.
Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) along with partner J&J gains approval for two-drug HIV regimen Juluca from the Japanese Ministry of Health, Labour and Welfare to benefit patients in the country.
Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors
by Zacks Equity Research
Bayer (BAYRY) receives the FDA approval for larotrectinib for the treatment of adult and pediatric patients having solid tumors with NTRK gene fusion.